logo

For the Inventor, By the Inventor

Paris, France

Matthew P Pando

This inventor holds 5 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Exonhit Therapeutics, Sa, Allergan, Inc.. Active years: 2010-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew P Pando. Retrieved from https://idiyas.com/inventor/matthew-p-pando

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 80.0

 

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Arlington, VA (US) (2010)
  • Paris, FR (2014 - 2018)

Company Filing History:

goldMedal5 out of 25 
 
Exonhit Therapeutics, Sa
 patents
silverMedal4 out of 2,287 
 
Allergan, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2010-2018

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents
1. 9902710 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2018-02-27),
2. 9670181 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2017-06-06),
3. 9200016 - Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) (2015-12-01),
4. 8772316 - Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) (2014-07-08),
5. 7834163 - Prostate specific genes and the use thereof as targets for prostate cancer therapy (2010-11-16),

Title: The Innovative Contributions of Matthew P Pando

Introduction

Matthew P Pando is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target phosphodiesterase 10 (PDE 10A). With a total of five patents to his name, Pando's work has implications for treating various central nervous system diseases and metabolic disorders.

Latest Patents

Pando's latest patents include the invention of substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A). These compounds are designed to be useful in treating central nervous system diseases such as psychosis. Additionally, they have potential applications in addressing obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain, and ophthalmic diseases. Another patent focuses on substituted 6,7-dialkoxy-3-isoquinolinol derivatives, which share similar therapeutic uses.

Career Highlights

Throughout his career, Matthew P Pando has worked with prominent companies in the pharmaceutical industry. He has been associated with Exonhit Therapeutics and Allergan, Inc., where he contributed to innovative research and development efforts. His work has been instrumental in advancing therapeutic options for patients with complex health conditions.

Collaborations

Pando has collaborated with esteemed colleagues, including Bertrand Leblond and Thierry Taverne. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in the pharmaceutical field.

Conclusion

Matthew P Pando's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in treating various health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…